加载中
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.
常规交易时段
US$2.95
−US$0.10 · -3.28%
盘中时间采用ET。市场数据可能有所延迟。
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.
日内区间
当前US$2.95
52周区间
当前US$2.95
盘中时间采用ET。市场数据可能有所延迟。
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.
日内区间
当前US$2.95
52周区间
当前US$2.95
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 59.01万 USD | 246.73万 USD | — | 76.63万 USD | 827 USD |
| 销货成本 | 51.53万 USD | 67.02万 USD | 554 USD | 31.9万 USD | 88 USD |
| 毛利 | 7.48万 USD | 179.71万 USD | −554 USD | 44.73万 USD | 739 USD |
| 研究与开发 | 14.7万 USD | 10.47万 USD | 7410 USD | 22.87万 USD | 12.36万 USD |
| 销售、一般及管理费用 | 162.4万 USD | 85.58万 USD | 113.3万 USD | 172.94万 USD | 63.43万 USD |
| 营业费用 | 745.15万 USD | 366.36万 USD | 114.04万 USD | 223.56万 USD | 78.58万 USD |
| 利息收入 | 11.8万 USD | 1.29万 USD | 5564 USD | 7702 USD | — |
| 利息支出 | 54.71万 USD | 73.52万 USD | — | 2629 USD | — |
| 折旧和摊销 | 11.05万 USD | 1.3万 USD | 1.16万 USD | 6512 USD | 2757 USD |
| 营业利润 | −737.67万 USD | −186.66万 USD | −114.1万 USD | −178.83万 USD | −78.51万 USD |
| 净利润 | −770.81万 USD | −624.57万 USD | −430.15万 USD | −180.03万 USD | −78.47万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年8月21日 | 1:10 | — | — |
股票拆分 | 2026年3月10日 | 1:6 | — | — |
股票拆分 | 2026年1月6日 | 1:4 | — | — |
股票拆分 | 2025年9月2日 | 2:7 | — | — |
股票拆分 | 2025年3月10日 | 1:7 | — | — |
股票拆分 | 2024年11月27日 | 1:200 | — | — |
已生效 2026年8月21日
1:10
已生效 2026年3月10日
1:6
已生效 2026年1月6日
1:4
已生效 2025年9月2日
2:7
已生效 2025年3月10日
1:7
已生效 2024年11月27日
1:200
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
